Mary Ellen Vajravelu1, Jinghua Chai1, Bryan Krock2, Samuel Baker2, David Langdon1,3, Craig Alter1,3, Diva D De León1,3. 1. Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 2. Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 3. Department of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
Context: Persistent hypoglycemia in the newborn period most commonly occurs as a result of hyperinsulinism. The phenotype of hypoketotic hypoglycemia can also result from pituitary hormone deficiencies, including growth hormone and adrenocorticotropic hormone deficiency. Forkhead box A2 (Foxa2) is a transcription factor shown in mouse models to influence insulin secretion by pancreatic β cells. In addition, Foxa2 is involved in regulation of pituitary development, and deletions of FOXA2 have been linked to panhypopituitarism. Objective: To describe an infant with congenital hyperinsulinism and hypopituitarism as a result of a mutation in FOXA2 and to determine the functional impact of the identified mutation. Main Outcome Measure: Difference in wild-type (WT) vs mutant Foxa2 transactivation of target genes that are critical for β cell function (ABCC8, KNCJ11, HADH) and pituitary development (GLI2, NKX2-2, SHH). Results: Transactivation by mutant Foxa2 of all genes studied was substantially decreased compared with WT. Conclusions: We report a mutation in FOXA2 leading to congenital hyperinsulinism and hypopituitarism and provide functional evidence of the molecular mechanism responsible for this phenotype.
Context: Persistent hypoglycemia in the newborn period most commonly occurs as a result of hyperinsulinism. The phenotype of hypoketotic hypoglycemia can also result from pituitary hormone deficiencies, including growth hormone and adrenocorticotropic hormone deficiency. Forkhead box A2 (Foxa2) is a transcription factor shown in mouse models to influence insulin secretion by pancreatic β cells. In addition, Foxa2 is involved in regulation of pituitary development, and deletions of FOXA2 have been linked to panhypopituitarism. Objective: To describe an infant with congenital hyperinsulinism and hypopituitarism as a result of a mutation in FOXA2 and to determine the functional impact of the identified mutation. Main Outcome Measure: Difference in wild-type (WT) vs mutant Foxa2 transactivation of target genes that are critical for β cell function (ABCC8, KNCJ11, HADH) and pituitary development (GLI2, NKX2-2, SHH). Results: Transactivation by mutant Foxa2 of all genes studied was substantially decreased compared with WT. Conclusions: We report a mutation in FOXA2 leading to congenital hyperinsulinism and hypopituitarism and provide functional evidence of the molecular mechanism responsible for this phenotype.
Authors: Changhong Li; Pan Chen; Andrew Palladino; Srinivas Narayan; Laurie K Russell; Samir Sayed; Guoxiang Xiong; Jie Chen; David Stokes; Yasmeen M Butt; Patricia M Jones; Heather W Collins; Noam A Cohen; Akiva S Cohen; Itzhak Nissim; Thomas J Smith; Arnold W Strauss; Franz M Matschinsky; Michael J Bennett; Charles A Stanley Journal: J Biol Chem Date: 2010-07-29 Impact factor: 5.157
Authors: Marcela M França; Alexander A L Jorge; Luciani R S Carvalho; Everlayny F Costalonga; Gabriela A Vasques; Claudia C Leite; Berenice B Mendonca; Ivo J P Arnhold Journal: J Clin Endocrinol Metab Date: 2010-08-04 Impact factor: 5.958
Authors: Binita M Kamath; Brian D Thiel; Xiaowu Gai; Laura K Conlin; Pedro S Munoz; Joseph Glessner; Dinah Clark; Daniel M Warthen; Tamim H Shaikh; Ercan Mihci; David A Piccoli; Struan F A Grant; Hakon Hakonarson; Ian D Krantz; Nancy B Spinner Journal: Hum Mutat Date: 2009-03 Impact factor: 4.878
Authors: Kristen A Lantz; Marko Z Vatamaniuk; John E Brestelli; Joshua R Friedman; Franz M Matschinsky; Klaus H Kaestner Journal: J Clin Invest Date: 2004-08 Impact factor: 14.808
Authors: Ritika R Kapoor; Chela James; Sarah E Flanagan; Sian Ellard; Simon Eaton; Khalid Hussain Journal: J Clin Endocrinol Metab Date: 2009-05-05 Impact factor: 5.958
Authors: N J Sund; M Z Vatamaniuk; M Casey; S L Ang; M A Magnuson; D A Stoffers; F M Matschinsky; K H Kaestner Journal: Genes Dev Date: 2001-07-01 Impact factor: 11.361
Authors: Sebastian Alexis Vishnopolska; Maria Florencia Mercogliano; Maria Andrea Camilletti; Amanda Helen Mortensen; Debora Braslavsky; Ana Keselman; Ignacio Bergadá; Federico Olivieri; Lucas Miranda; Roxana Marino; Pablo Ramírez; Natalia Pérez Garrido; Helen Patiño Mejia; Marta Ciaccio; Maria Isabel Di Palma; Alicia Belgorosky; Marcelo Adrian Martí; Jacob Otto Kitzman; Sally Ann Camper; Maria Ines Pérez-Millán Journal: J Clin Endocrinol Metab Date: 2021-06-16 Impact factor: 6.134
Authors: Maria Gϋemes; Sofia Asim Rahman; Ritika R Kapoor; Sarah Flanagan; Jayne A L Houghton; Shivani Misra; Nick Oliver; Mehul Tulsidas Dattani; Pratik Shah Journal: Rev Endocr Metab Disord Date: 2020-12 Impact factor: 6.514